Agreed! Young biotechs take on healthy levels of debt whilst developing interesting science (such as successful "IDO silencing in human cells"!), and recoup when they prove the drug/treatment through big pharma interest/licensing. At this point in the game we can't expect to see revenues, or anything but increasing debt for that matter.
News 
Market Data 
Discover 
AI
